Exercise Mimetics for Dementia and Alzheimer's Disease

治疗痴呆和阿尔茨海默病的模拟运动

基本信息

  • 批准号:
    10586188
  • 负责人:
  • 金额:
    $ 226.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-01 至 2026-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary Dementia or major neurocognitive disorder is a condition of significant cognitive decline that impairs independent living. Learning and memory, executive function, perceptual-motor function, social cognition, and language may be affected. Although dementia is typically associated with aging, it is not a natural component of the aging process. Dementia is associated with several diseases, but most commonly associated with AD (60-80%). AD is a progressive neurodegenerative disease with clinical features that include memory loss, cognitive impairment and dementia. More than 5 million Americans currently live with AD and it is expected to increase to as much as 16 million by 2050. Ten percent of individuals over the age of 65 in the U.S. currently have AD. Current treatments for AD have limited efficacy and there is a significant need for improved pharmacological therapies. AD is characterized by the formation of senile plaques and neurofibrillary tangles in the grey matter of affected individuals. The senile plaques are composed of extracellular deposition of insoluble amyloid beta (Aβ) peptides that are typically associated with a wealth of microglia (brain resident macrophages) and astrocytes. ERRs are orphan receptors that play a key role in regulation of oxidative metabolism, and we have discovered that they function as exercise mimetics and enhance cognitive function in normal and aged mice as well as decrease amyloid plaques in animal models of AD. The goal of this project is to develop optimized ERR agonists that may be effective agents in treatment of dementia and Alzheimer's disease.
项目摘要 痴呆或主要神经认知障碍是一种显著的认知下降的状况, 独立生活。学习和记忆、执行功能、感知运动功能、社会认知和 语言可能会受到影响。虽然痴呆症通常与衰老有关,但它不是一个自然组成部分 衰老过程的一部分。痴呆症与几种疾病有关,但最常见的是与AD有关 (60-80%)。AD是一种进行性神经退行性疾病,其临床特征包括记忆丧失, 认知障碍和痴呆。目前有超过500万美国人患有AD,预计 到2050年增加到1600万。目前,美国65岁以上的人中有10% 有AD。目前用于AD的治疗具有有限的功效,并且显著需要改进的治疗。 药物治疗AD的特征是老年斑和神经元缠结的形成, 受影响个体的灰质。老年斑是由细胞外沉积的 不溶性淀粉样β(Aβ)肽,通常与大量小胶质细胞(脑内驻留 巨噬细胞)和星形胶质细胞。ERRs是孤儿受体,在调节氧化应激中起关键作用。 代谢,我们已经发现它们作为运动模拟物发挥作用,并增强认知功能, 正常和老年小鼠以及减少AD动物模型中的淀粉样斑块。这个项目的目标是 开发优化的ERR激动剂,可能是治疗痴呆和阿尔茨海默病的有效药物, 疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas P Burris其他文献

How to Make Glucocorticoids Safer.
PPARα ligands make memories
过氧化物酶体增殖物激活受体α配体形成记忆
  • DOI:
    10.1038/nchembio.2241
  • 发表时间:
    2016-11-15
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Thomas P Burris
  • 通讯作者:
    Thomas P Burris

Thomas P Burris的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas P Burris', 18)}}的其他基金

Targeting REV-ERB to treat Alzheimer's disease
靶向 REV-ERB 治疗阿尔茨海默病
  • 批准号:
    10675294
  • 财政年份:
    2019
  • 资助金额:
    $ 226.29万
  • 项目类别:
ERRgamma Agonists to Treat Muscular Dystrophy
ERRgamma 激动剂治疗肌营养不良症
  • 批准号:
    9176946
  • 财政年份:
    2016
  • 资助金额:
    $ 226.29万
  • 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
  • 批准号:
    8898423
  • 财政年份:
    2012
  • 资助金额:
    $ 226.29万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8915743
  • 财政年份:
    2012
  • 资助金额:
    $ 226.29万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8237792
  • 财政年份:
    2012
  • 资助金额:
    $ 226.29万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8578608
  • 财政年份:
    2012
  • 资助金额:
    $ 226.29万
  • 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
  • 批准号:
    8444102
  • 财政年份:
    2012
  • 资助金额:
    $ 226.29万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    9116001
  • 财政年份:
    2012
  • 资助金额:
    $ 226.29万
  • 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
  • 批准号:
    8370510
  • 财政年份:
    2010
  • 资助金额:
    $ 226.29万
  • 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
  • 批准号:
    8209001
  • 财政年份:
    2010
  • 资助金额:
    $ 226.29万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 226.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了